Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Ruth Lapushin"'
Autor:
William K Decker, Nina Shah, Dongxia Xing, Ruth Lapushin, Sufang Li, Simon N Robinson, Hong Yang, Simrit Parmar, Matthew M Halpert, Michael J Keating, John G Gribben, Jeffrey J Molldrem, Elizabeth J Shpall, William G Wierda
Publikováno v:
PLoS ONE, Vol 7, Iss 12, p e51390 (2012)
Though remissions have been observed following allo-HSCT for the treatment of CLL, many CLL patients are ineligible for transplant due to the lack of HLA-compatible donors. The use of umbilical cord blood (UCB) permits transplantation of many patient
Externí odkaz:
https://doaj.org/article/755950a4c5214302be9eb8cac96b0847
Autor:
Ruth LaPushin, H. Yang, Simon N. Robinson, Dongxia Xing, William G. Wierda, William K. Decker, Shawndeep Tung, Marcelo Fernandez-Vina, Simrit Parmar, Susan O'Brien, Elizabeth J. Shpall, Nina Shah
Publikováno v:
Leukemia. 25:1036-1039
HLA homozygosity and haplotype bias among patients with chronic lymphocytic leukemia: implications for disease control by physiological immune surveillance
Autor:
Shuying Liu, Shuangxing Yu, Hong Ji Xu, Xianjun Fang, Ruth LaPushin, Yutaka Hasegawa, Gordon B. Mills, James R. Woodgett
Publikováno v:
Journal of Biological Chemistry. 279:51075-51081
The c-Jun N-terminal kinase (JNK)/stress activated protein kinase is preferentially activated by stress stimuli. Growth factors, particularly ligands for G protein-coupled receptors, usually induce only modest JNK activation, although they may trigge
Autor:
Judith K. Wolf, Astrid Eder, Binglian Fang, Jian Gu, Nelly Auersperg, Fazal H. Tabassam, Gordon B. Mills, Jack A. Roth, Ruth LaPushin, Janos L. Tanyi
Publikováno v:
Gynecologic Oncology. 85:451-458
Objective. One potential limitation of gene therapy for epithelial tumors is the lack of tissue or tumor specificity of treatment. Tumor-selective expression of gene therapies may avoid deleterious side effects and improve the efficacy of the treatme
Autor:
Xianjun FANG, Shuangxing YU, Ruth LAPUSHIN, Yiling LU, Tatsuro FURUI, Linda Z. PENN, David STOKOE, James R. ERICKSON, Robert C. BAST, Gordon B. MILLS
Publikováno v:
Biochemical Journal. 352:135-143
Lysophosphatidic acid (LPA) is a naturally occurring phospholipid with multiple biological functions. In the present study, we demonstrate that, besides its mitogenic activity, LPA is a potent survival factor, preventing serum-deprivation-induced apo
Autor:
Ruth LaPushin, Mary L. Browning, Alessandra Ferrajoli, Susan O'Brien, William G. Wierda, Michael J. Keating, Stefan Faderl
Publikováno v:
European Journal of Haematology. 80:296-298
We evaluated the activity and tolerability of alemtuzumab given as a continuous infusion for 7 d followed by subcutaneous administration for 11 wk as salvage therapy for 10 patients with fludarabine-refractory chronic lymphocytic leukemia. The contin
Publikováno v:
Biochemical and Biophysical Research Communications. 247:379-382
p202 is an interferon (IFN)-inducible, primarily nuclear, phosphoprotein (52-kDa) whose overexpression in transfected cells inhibits colony formation. p202 binds to the retinoblastoma tumor suppressor protein and two other members of the pocket famil
Autor:
Humera Khan, Ruth LaPushin, Kenneth E. Truitt, Spencer Gibson, Yiling Lu, Gordon B. Mills, John B. Imboden
Publikováno v:
Scopus-Elsevier
Optimal T cell activation requires crosslinking of the T cell receptor (TCR) concurrently with an accessory receptor, most efficiently CD28. Crosslinking of CD28 leads to increased interleukin 2 (IL2) production, inhibition of anergy and prevention o
Publikováno v:
Journal of Interferon & Cytokine Research. 16:259-267
Like tumor necrosis factor (TNF), antibodies against the Fas antigen (anti-Fas) are cytotoxic to some and induce proliferation of other Fas-expressing cells. In this study, we compared cellular responses mediated through TNF with anti-Fas using a T c
Autor:
Zeev Estrov, Babru B Samal, Pirkko Kellokumpu-Lehtinen, Razelle Kurzrock, Ruth LaPushin, Moshe Talpaz, Aysegul A. Sahin, Bharat B. Aggarwal
Publikováno v:
Journal of Interferon & Cytokine Research. 15:905-913
Leukemia inhibitory factor (LIF) is a cytokine that was originally described as a differentiation factor of a murine myeloid leukemia cell line and subsequently found to be an important mediator of embryonic development. Although extensively studied